Biotech IPO Window Reopens; Big Pharma Accelerates Genomics M&A
JPMorgan’s healthcare dealmakers say public markets are reopening for biotech, but buyers remain selective. High-quality assets may exit via M&A or IPO through dual-tracks, with Big Pharma funding larger bets. EY notes first-in-class momentum and new financing models, signaling catalysts for ARKG holdings over the next 6–12 months.
View signal analysis